



**Specimen Details**

**Date collected:** 03/29/2019 0839 Local  
**Date received:** 03/29/2019  
**Date entered:** 03/29/2019  
**Date reported:** 03/31/2019 1606 ET

**General Comments & Additional Information**

**Total Volume:** Not Provided

**Fasting:** Yes

**Ordered Items**

NMR LipoProfile; CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel; Hemoglobin A1c; Cortisol; C-Reactive Protein, Cardiac; Insulin; Venipuncture

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
<b>NMR LipoProfile</b>					
LDL Particle Number					01
<b>LDL-P</b>	<b>1020</b>	<b>High</b>	nmol/L	<1000	01
		<b>Low</b>		< 1000	
		<b>Moderate</b>		1000 - 1299	
		<b>Borderline-High</b>		1300 - 1599	
		<b>High</b>		1600 - 2000	
		<b>Very High</b>		> 2000	
Lipids					01
<b>LDL-C</b>	<b>72</b>		mg/dL	0 - 99	01
		<b>Optimal</b>		< 100	
		<b>Above optimal</b>		100 - 129	
		<b>Borderline</b>		130 - 159	
		<b>High</b>		160 - 189	
		<b>Very high</b>		> 189	
Comment:					01
LDL-C is inaccurate if patient is non-fasting.					
<b>HDL-C</b>	<b>29</b>	<b>Low</b>	mg/dL	>39	01
<b>Triglycerides</b>	<b>208</b>	<b>High</b>	mg/dL	0 - 149	01
Cholesterol, Total	143		mg/dL	100 - 199	01
LDL and HDL Particles					01
<b>HDL-P (Total)</b>	<b>24.4</b>	<b>Low</b>	umol/L	>=30.5	01
<b>Small LDL-P</b>	<b>594</b>	<b>High</b>	nmol/L	<=527	01
<b>LDL Size</b>	<b>20.4</b>	<b>Low</b>	nm	>20.5	01

**\*\* INTERPRETATIVE INFORMATION\*\***

**PARTICLE CONCENTRATION AND SIZE**

**<--Lower CVD Risk Higher CVD Risk-->**

LDL AND HDL PARTICLES	Percentile	in Reference Population	50th	25th	Low
<b>HDL-P (total)</b>	<b>High</b>	<b>75th</b>	<b>30.5</b>	<b>26.7</b>	<b>&lt;26.7</b>
	<b>&gt;34.9</b>	<b>34.9</b>	<b>50th</b>	<b>75th</b>	<b>High</b>
<b>Small LDL-P</b>	<b>Low</b>	<b>25th</b>	<b>527</b>	<b>839</b>	<b>&gt;839</b>
	<b>&lt;117</b>	<b>117</b>			
<b>LDL Size</b>	<b>&lt;-Large (Pattern A)-&gt;</b>		<b>&lt;-Small (Pattern B)-&gt;</b>		

Patient ID:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
	23.0	20.6	20.5	19.0	

Comment: 01

Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.

These assays were developed and their performance characteristics determined by LipoScience. These assays have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values have not been fully established.

Insulin Resistance Score 01

LP-IR Score 100 High <=45 01

**INSULIN RESISTANCE MARKER**

<--Insulin Sensitive Insulin Resistant-->

Percentile in Reference Population

**Insulin Resistance Score**

LP-IR Score	Low	25th	50th	75th	High
	<27	27	45	63	>63

Comment: 01

LP-IR Score is inaccurate if patient is non-fasting. The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment. The LP-IR score listed above has not been cleared by the US Food and Drug Administration.

**CBC With Differential/Platelet**

WBC	4.3	K/uL	3.2 - 10.6	02
RBC	5.28	M/uL	3.98 - 5.98	02
Hemoglobin	15.9	g/dL	12.5 - 18.0	02
Hematocrit	46.6	%	36.9 - 52.1	02
MCV	88.3	fL	80.6 - 97.6	02
MCH	30.1	pg	27.3 - 33.7	02
MCHC	34.1	g/dL	33.4 - 35.3	02
RDW	14.2	%	12.5 - 15.3	02
Platelets	291	K/uL	140 - 440	02
Neutrophils	53.6	%	41.0 - 81.0	02
Lymphs	34.4	%	11.0 - 44.0	02
Monocytes	9.5	%	4.0 - 11.0	02
Eos	1.4	%	0.0 - 6.0	02
Basos	0.9	%	0.0 - 1.0	02
Neutrophils (Absolute)	2.3	K/uL	1.8 - 6.8	02
Lymphs (Absolute)	1.5	K/uL	1.0 - 3.0	02
Monocytes (Absolute)	0.4	K/uL	0.2 - 1.0	02
Eos (Absolute)	0.1	K/uL	0.0 - 0.4	02
Baso (Absolute)	0.0	K/uL	0.0 - 0.1	02
Immature Granulocytes	0.2	%	0.0 - 8.0	02

Patient ID:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Immature Grans (Abs)	0.0		K/uL	0.0 - 1.9	02
NRBC	0		/100WBC		02
Hematology Comments:					02
RDW SD	45.1		fL	N	
MEAN PLATELET VOLUME	11.1		fL	6.2-9.8 H	
<b>Comp. Metabolic Panel (14)</b>					
Glucose	75		mg/dL	70 - 110	02
BUN	14		mg/dL	7 - 18	02
Creatinine	0.90		mg/dL	0.60 - 1.30	02
eGFR If NonAfricn Am	92.99		mL/min		02
GFR calculation is only for patients with chronic renal insufficiency. Units of measure are ml/min/1.73 m2.					
Average GFR for healthy adults is >60 ml/min/1.73 m2					
Chronic kidney disease if GFR is 15-60 ml/min/1.73 m2					
Kidney failure if GFR is <15 ml/min/1.73 m2					
MDRD calculation used. Refer to <a href="http://www.nkdep.nih.gov/healthprofessionals/index.htm">http://www.nkdep.nih.gov/healthprofessionals/index.htm</a>					
eGFR If Africn Am	119.59		mL/min		02
GFR calculation is only for patients with chronic renal insufficiency. Units of measure are ml/min/1.73 m2.					
Average GFR for healthy adults is >60 ml/min/1.73 m2					
Chronic kidney disease if GFR is 15-60 ml/min/1.73 m2					
Kidney failure if GFR is <15 ml/min/1.73 m2					
MDRD calculation used. Refer to <a href="http://www.nkdep.nih.gov/healthprofessionals/index.htm">http://www.nkdep.nih.gov/healthprofessionals/index.htm</a>					
BUN/Creatinine Ratio	15.6		Ratio	7.0 - 24.0	02
Sodium	141		mmol/L	136 - 145	02
Potassium	4.9		mmol/L	3.5 - 5.1	02
Chloride	102		mmol/L	98 - 107	02
Carbon Dioxide, Total	28		mmol/L	23 - 32	02
Calcium	8.8		mg/dL	8.5 - 10.1	02
Protein, Total	6.9		g/dL	6.4 - 8.2	02
Albumin	4.1		g/dL	3.4 - 5.0	02
Globulin, Total	2.8		g/dL	1.8 - 3.5	02
A/G Ratio	1.5				02
Bilirubin, Total	0.7		mg/dL	0.1 - 1.2	02
Alkaline Phosphatase	58		U/L	50 - 136	02
AST (SGOT)	26		U/L	5 - 41	02
ALT (SGPT)	22		U/L	10 - 56	02
<b>Lipid Panel</b>					
Cholesterol, Total	146		mg/dL	0 - 200	02

Patient ID:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Triglycerides	199	High	mg/dL	0 - 150	02
HDL Cholesterol	34	Low	mg/dL	40 - 60	02

**Male patients:**

No risk >55 mg/dL  
 Moderate risk = 40-55 mg/dL  
 High risk <40 mg/dL

**Female patients:**

No risk >65 mg/dL  
 Moderate risk = 45-65 mg/dL  
 High risk <45 mg/dL

**National Cholesterol Education Program (NCEP Guidelines:**

<40mg/dL = low HDL cholesterol (major risk of CHD)  
 >60 mg/dL = high HDL cholesterol (negative risk factor for CHD)

VLDL Cholesterol Cal	39.8	High	mg/dL	2 - 30	02
LDL Cholesterol Calc	72		mg/dL	0 - 130	02

**Adults:**

Desirable LDL <130 mg/dl  
 Borderline LDL = 130-160 mg/dl  
 High Risk LDL >160 mg/dl

**Children <19 Years of Age:**

Desirable LDL <110 mg/dl  
 Borderline LDL = 110-130 mg/dl  
 High Risk LDL >130 mg/dl

<b>Hemoglobin A1c</b>	4.9		%	4.2 - 6.3	02
-----------------------	-----	--	---	-----------	----

For management of known diabetes, Hgb A1c level goals must be individualized for each patient. Age, type of diabetes, presence of comorbid diseases, and brittleness of the disease must be considered. In general, a level of 7% is a reasonable goal.

Performance characteristics for this method have not been established or approved by the FDA for the diagnosis of diabetes.

<b>Cortisol</b>	7.4		ug/dL		03
			Cortisol AM	6.2 - 19.4	
			Cortisol PM	2.3 - 11.9	

<b>C-Reactive Protein, Cardiac</b>	1.31		mg/L	0.00 - 3.00	03
			Relative Risk for Future Cardiovascular Event		
			Low	<1.00	

Patient ID:

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
			Average	1.00	- 3.00	
			High		>3.00	
<b>Insulin</b>	4.4		uIU/mL	2.6	- 24.9	03

01	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: Sanjai Nagendra, MD
02	DRAUT	Lone Peak Hospital 11925 S State Street, Draper, UT 84020-7735	Dir: Nathan Eliason, MD
03	PDLCA	LabCorp Phoenix 5005 S 40th Street Ste 1200, Phoenix, AZ 85040-2969	Dir: Earle Collum, MD

For inquiries, the physician may contact **Branch: 888-522-2677 Lab: 800-762-4344**